Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Garp1on Nov 19, 2015 5:39am
232 Views
Post# 24304112

RE:RE:RE:Mackie

RE:RE:RE:MackieOnce again, perception is reality. This market is driven by analyst expectations and numbers. If you fail to beat, meet or manage those expectations the market will judge you as such and this regardless of past performances of the company. Time and time again, Theratechnologies as always failed to provide, determine or manage information to guide analysts in their forward looking assessment. Invoking past achievements based on objectives largely only known by them is insufficient for the investor community to promote growth in the stock price and at best can only maintain it. Theratechnologies as resolved some past issues and is now showing progress but the Investment community looks towards the analysts to tell them if the company is growing. A series of good press release as propelled this stock to new highs, but the challenge for Theratechnologies now is to convince analysts that they have a plan and that they will meet it or exceed it. Left with a void, analysts will form their own idea of what Theratechnologies plan is and inform the investment community accordingly.
Bullboard Posts